ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy

Author(s): Martin David Harp

Key Takeaways

• Xelafaslatide, a Fas inhibitor, shows promise in protecting retinal cells and slowing GA progression in dry AMD.
• The phase 1b study evaluated safety and tolerability through dose-escalation and natural history/treatment components.
• Results indicated improved BCVA and slower lesion growth with xelafaslatide, particularly at higher doses.
• Xelafaslatide’s unique mechanism offers potential for reduced treatment burden and enhanced neuroprotection in GA.

Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions.

ONL Therapeutics has released data from its phase 1b study of xelafaslatide (formerly known as ONL1204 ophthalmic solution) for the treatment of geographic atrophy (GA).

According to the company, xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions, including GA associated with dry age-related macular degeneration (AMD).

Read more: ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy | Ophthalmology Times – Clinical Insights for Eye Specialists

Source: Ophthalmology Times